Published • loading... • Updated
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress
Summary by Helena Independent Record
26 Articles
26 Articles
Helena Independent Record+25 Reposted by 25 other sources
Innovent Announces Phase 2 Results of Tigulixostat (IBI128, XOI) in Gout Patients were Published at the 27th Asia-Pacific League of Associations for Rheumatology Congress
SAN FRANCISCO and SUZHOU, China, Sept. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major…
·Helena, United States
Read Full ArticleCoverage Details
Total News Sources26
Leaning Left1Leaning Right0Center15Last UpdatedBias Distribution94% Center
Bias Distribution
- 94% of the sources are Center
94% Center
C 94%
Factuality
To view factuality data please Upgrade to Premium
